Targovax ASA is a clinical-stage immuno-oncology company based in Oslo, Norway, focused on developing oncolytic viruses and neoantigen cancer vaccines to treat challenging solid tumors. Its lead product, ONCOS-102, is currently undergoing Phase I/II clinical trials for various cancers, including mesothelioma, melanoma, peritoneal disease, and prostate cancer. Additionally, Targovax is advancing TG01, a cancer vaccine in Phase I/II trials for resectable pancreatic cancer, which aims to activate the immune system to target specific RAS mutations in cancer cells. The company collaborates with notable organizations, including Cancer Research Institute, Ludwig Cancer Research, and AstraZeneca, to enhance the development of its therapies. Targovax's innovative approach aims to induce robust immune responses by leveraging both helper and cytotoxic T-cell mechanisms, demonstrating potential for improved patient survival and favorable tolerability profiles. Established in 2010 by inventors from the Radium Hospital Research Foundation, Targovax is dedicated to addressing unmet medical needs in oncology.